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Purpose. 123I-metaiodobenzylguanidine (MIBG) is used for the diagnostic evaluation of neuroblastoma. We evaluated the
relationship between norepinephrine transporter (NET) expression and clinical MIBG uptake. Methods. Quantitative reverse
transcription PCR (N = 82) and immunohistochemistry (IHC; N = 61) were performed for neuroblastoma NET mRNA and
protein expression and correlated with MIBG avidity on diagnostic scans. The correlation of NET expression with clinical features
was also performed. Results. Median NET mRNA expression level for the 19 MIBG avid patients was 12.9% (range 1.6–73.7%)
versus 5.9% (range 0.6–110.0%) for the 8 nonavid patients (P = 0.31). Median percent NET protein expression was 50% (range
0–100%) in MIBG avid patients compared to 10% (range 0–80%) in nonavid patients (P = 0.027). MYCN amplified tumors
had lower NET protein expression compared to nonamplified tumors (10% versus 50%; P = 0.0002). Conclusions. NET protein
expression in neuroblastoma correlates with MIBG avidity. MYCN amplified tumors have lower NET protein expression.
1. Introduction
Metaiodobenzylguanidine (MIBG) is an agent that is specifi-
cally taken up by sympathetic nervous system tissues, includ-
ing neuroblastoma tumors. 123I-MIBG plays an essential
role in the diagnostic evaluation of patients with neurob-
lastoma [1]. In addition, high-dose 131I-MIBG therapy is an
important part of the treatment of patients with relapsed or
refractory neuroblastoma [2].
The norepinephrine transporter (NET; encoded by
SLC6A2 gene) is thought to be the primary transporter
responsible for specific active cellular uptake of MIBG [3].
Several studies have demonstrated that neuroblastoma cell
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lines that lack NET mRNA expression fail to accumulate
MIBG [4–6]. NET mRNA levels appear to correlate in vitro
with extent of MIBG uptake [6–8]. Moreover, a range of cells
that do not typically accumulate MIBG can be engineered
to do so by transfection of the NET gene [9–17]. Addi-
tional studies in neuroblastoma and other neuroendocrine
tumors have suggested that vesicular monoamine trans-
porters (VMATs) and organic cation transporters (OCTs)
may also play a role in mediating uptake of MIBG [18–20].
Approximately 10% of patients with neuroblastoma have
tumors that do not accumulate MIBG on the basis of
negative diagnostic 123I-MIBG scans [21]. The determinants
of MIBG-avidity in clinical neuroblastoma tumors are
unknown. One small study utilized RT-PCR to evaluate NET
gene expression in 6 neuroblastoma tumors from patients
with negative baseline MIBG diagnostic scans [4]. None
of these tumors had detectable NET mRNA, while 90% of
the 48 MIBG-avid tumors had detectable NET transcripts.
Other groups have not yet replicated these results. Moreover,
the correlation between clinical MIBG uptake with NET
protein expression and mRNA expression of other putative
MIBG transporters has not been studied. The primary
aim of the current study was to determine the association
between tumor NET mRNA and protein expression with
MIBG avidity in patients with neuroblastoma. Secondary
aims included evaluation of the association of SLC6A2 gene
polymorphisms with MIBG avidity, association of mRNA
expression for other membrane transporters with MIBG
avidity, as well as correlation of NET protein expression levels
with clinical features.
2. Materials andMethods
2.1. Patients and Treatment. Patients were selected from
Children’s Oncology Group (COG) protocols A3961 and
A3973 for the treatment of intermediate-risk or high-risk
neuroblastoma, respectively [22, 23]. For the primary analy-
ses focused on NET expression, all patients with institutional
report of MIBG nonavid tumors and available tumor mRNA
were included (n = 29). An unselected group of patients
with institutional report of MIBG avid tumors and available
tumor mRNA was also included (n = 54) to achieve the
desired sample size for the primary analyses.
For evaluation of NET genotype, patients from A3961
and A3973 who had been included in a previous large-
scale neuroblastoma genome-wide association project were
included [24, 25]. Patients were treated according to protocol
therapy, as previously described [22, 23]. All laboratories
performing RT-PCR, immunohistochemistry, and genotyp-
ing were blinded to patient characteristics, including MIBG
avidity.
All participants or legal guardians provided consent for
use of submitted tissue at the time of initial enrollment
onto a COG or legacy group neuroblastoma biology study.
The COG Neuroblastoma Biology Committee and the UCSF
Committee on Human Research approved the study.
2.2. MIBG Scans and Central Review. Patients underwent
diagnostic 123I- or 131I-MIBGwhole body scans at the time of
study entry onto either clinical trial A3973 or A3961. Scans
were obtained according to local institutional practice and
coded as MIBG avid or nonavid by the treating investigator.
Baseline diagnostic MIBG scans were available for central
review for 27 patients with high-risk disease treated on
protocol A3973 who also had tumor mRNA available for
analysis. The primary clinical endpoint for the current study,
MIBG avidity, is based upon the results of central review
in these 27 patients. Central review was independent of the
current study and preceded determination of tumor trans-
porter expression levels for the current study. Investigator
assessment of MIBG avidity was used only for evaluation of
correlation of NET gene polymorphisms with MIBG avidity.
2.3. Quantification of Tumor Transporter mRNA Expression.
Neuroblastoma tumor material from patients participating
in the COG neuroblastoma biology study was submitted
frozen to the Neuroblastoma Tumor Bank at the COG
Biopathology Center (Columbus, OH). For tumors with a
minimum of 60% neuroblastoma tumor in the submitted
material, RNA was extracted using Invitrogen Life Technolo-
gies TRIzol Reagent (Total RNA Isolation Reagent; Grand
Island, NY). RNA was stored at −80◦C until ready for
further testing. mRNA quality was assessed using either
RNA integrity number (RIN) or ratio of absorbance at 260
and 280 nm (A260/A280). RIN data were available for 17
samples, with a mean RIN of 6.6. For the remaining 66
samples, the mean A260/A280 ratio was 1.62.
Reverse transcriptase PCR (RT-PCR) was performed
with Applied Biosystem’s (ABI) High Capacity Reverse
Transcription Kit using 2 µg of total RNA as per manu-
facturer instructions. Quantitative real-time PCR (Q-PCR)
reactions were conducted with Taqman Fast Universal Mas-
ter Mix (ABI) in 384-well reaction plates using 10 ng of
cDNA per reaction. Commercial TaqMan probe and primer
sets for NET (Assay ID: Hs01567441 m1), OCT-1 (Assay
ID: Hs00427552 m1), OCT-2 (Assay ID: Hs00533907 m1),
OCT-3 (Assay ID: Hs01009568 m1), VMAT-1 (Assay ID:
Hs00915193 m1), VMAT-2 (Assay ID: Hs00161858 m1),
MATE-1 (Assay ID: Hs00217320 m1), GAPDH (Assay ID:
Hs99999905 m1), and PGK1 (Assay ID: Hs99999906 m1)
were purchased from ABI. Reactions were run on an ABI
Prism 7900HT, and the thermal cycling conditions were 95◦C
for 20 seconds followed by 60 cycles of 95◦C for 3 seconds
and 60◦C for 30 seconds. Amplification of GAPDH and
PGK1 mRNA were performed as internal controls. Gene
expression was normalized as the percent of GAPDH and
PGK1 expression. Results using either control were well
correlated (r2 = 0.91) such that only the results normalized
to PGK1 are presented. Negative controls with no added
cDNA showed no NET amplification. Expression vector
containing NET cDNA was used as a positive control and
demonstrated that NET expression levels in the tumor tissue
were within the linear range of the standard curve. All
samples were tested in triplicate, and the result reported is
the mean of three separate experiments.
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2.4. Immunohistochemistry for NET Protein Expression.
Paraffin-embedded tumor material was prepared using stan-
dard methods at each treating institution and submitted to
the COG Neuroblastoma Tumor Bank. Each of the forma-
lin fixed paraffin embedded glass slides was stained with
a commercially available NET antibody (NET17-1; MAb
Technologies; Stone Mountain, GA) at a 1 : 1000 dilution.
Antigen retrieval was performed in a pressure cooker with
0.01M-citrate buffer at a pH of 7.6. Slides were blocked using
the avidin biotin blocking kit (SP-2001; Vector Laboratories;
Burlingame, CA). Slides were incubated with the primary
antibody for 1 hour at room temperature. The secondary
antibody used was a biotinylated anti-mouse IgG 1 : 200 dilu-
tion (Vector). Slides were then incubated per manufacturer
protocol with an avidin biotin complex (Vector). Lastly, the
slides were incubated with diaminobenzidine using a high-
sensitivity substrate chromogen system (Dako; Carpinteria,
CA) and counterstained with hematoxylin. Pontine tissue
and lymph node tissue served as positive and negative
controls, respectively. Staining results were assessed by one
pathologist (BP) using a four point scoring system: 0+ =
tumor cells display complete lack of staining; 1+ = tumor
cells show faint cytoplasmic staining; 2+ = tumor cells show
intermediate cytoplasmic staining; 3+ = tumor cells display
intense cytoplasmic staining (see Supplemental Figure 1 for
representative sections in Suplementary Material available
online at doi:10.1155/2012/250834.) The percentage of cells
positive for NET by IHC was also determined (Supplemental
Figure 1). A NET protein expression composite score
was derived by multiplying the percentage of tumor cells
expressing NET by the intensity score.
2.5. NET Genotyping. Germline DNA was isolated and
genotyped as previously described [25]. In brief, the Illumina
HumanHap550 BeadChip was used to genotype samples at
over 550,000 single nucleotide polymorphisms (SNPs). From
this larger dataset, all SNPs in the NET gene (SLC6A2) locus
were chosen for analysis in the current study. While no SNPs
were excluded due to low minor allele frequencies, only 4
SNPs had minor allele frequencies <10%.
2.6. Statistical Methods. Given the sample size and nonnor-
mal distribution of transporter levels, the Wilcoxon rank
sum test was used to compare transporter expression levels
between patients with MIBG avid versus MIBG nonavid
tumors. The Fisher exact test was used to compare NET
protein intensity category between patients with MIBG avid
vs. MIBG nonavid tumors. The Wilcoxon rank sum test was
also used to compare NET protein levels between groups
defined by categorical clinical characteristics other than
MIBG avidity. Kaplan-Meier methods were used to estimate
event-free survival (EFS) from time of entry on to clinical
trial (A3961 or A3973) to disease progression, relapse, death
from any cause, or second malignancy. Patients without
event were censored at time of last followup. Differences
in EFS based on median NET protein expression levels
were assessed using the log-rank test. P values <0.05 were
considered statistically significant.
Genotyping data were coded based on the number
of copies of the minor allele present at each position
evaluated in the NET gene. Binomial tests for equality of
proportions were used to evaluate statistical associations
using a dominant genetic model, while logistic regression
was used to assess an additive genetic model. To adjust
for multiple testing, the R library [26] “q-value” [27] that
converts P values into corresponding false discovery rates
[28] was used.
3. Results
3.1. Patient Characteristics. Tumor mRNA was available for
83 patients treated on trials A3961 and A3973. One patient
with poor mRNA quality was excluded from further analysis.
The characteristics of the remaining 82 patients who form
the main analytic cohort are shown in Table 1. Thirty-one
patients had intermediate-risk and 51 patients had high-
risk neuroblastoma. Eighteen percent of patients had tumor
MYCN amplification. Sixty-four percent of patients in this
selected cohort had MIBG uptake on scan by institutional
report.
Of the 82 patients with available tumor mRNA, 27
patients had centrally reviewed MIBG scans. Of the 82
patients with available tumor mRNA, 61 also had paraffin
embedded tumor available for NET immunohistochemistry.
Of these 61 patients, 23 patients had centrally reviewed
MIBG scans.
3.2. NET mRNA Expression Does Not Correlate with MIBG
Avidity. Based on strong preclinical data implicating NET
as the primary transporter responsible for MIBG uptake, we
first evaluated the association between NET mRNA expres-
sion and clinical MIBG avidity. The distribution of NET
tumor mRNA expression according to centrally-reviewed
MIBG avidity is shown in Figure 1. This distribution
demonstrates extensive overlap in NET expression between
patients with and without MIBG avid tumors. The median
NET expression level for the 19 patients with MIBG avid
tumors was 12.9% (range 1.6–73.7%), while the median
NET expression level for the 8 patients with MIBG nonavid
tumors was 5.9% (range 0.6–110.0%; P = 0.31).
3.3. Polymorphisms in the SLC6A2 Gene Do Not Correlate
with MIBG Avidity. Germline genotype data for 26 SNPs
(Supplemental Table 1) in the SLC6A2 gene encoding NET
were available in 325 patients treated on protocols A3961
and A3973 who were included in a previous genome-wide
association study [24, 25]. For this analysis only, investigator
assessment of MIBG avidity, rather than central review
assessment of MIBG avidity, was used as the clinical outcome
of interest. This cohort included 276 MIBG avid and 49
MIBG nonavid patients. There was no correlation between
MIBG avidity and any of the SNP genotypes, using either
dominant or additive geneticmodels (Supplemental Table 1).
3.4. NET Protein Expression Correlates with MIBG Avidity.
Since neither NET mRNA expression nor SLC6A2 genotype
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Table 1: Characteristics of 82 patients with available tumor mRNA and of the subset of 27 patients with centrally reviewed MIBG diagnostic
scans.
Entire cohort (N = 82) Subset of patients centrally reviewed (N = 27)
Median age (range) 11.9 months (0.1–171.7 months) 33 months (3.8–171.7 months)
Age > 18 months at diagnosis 35/82 (42.7%) 22/27 (81%)
Intermediate-risk group : High-risk group 31 : 51 0 : 27
Adrenal primary tumor 38/82 (46.3%) 16/27 (59%)
Stage 4 : Stage 4S : Localized tumors 39 : 7 : 36 15 : 2 : 10
MYCN-amplified tumor 15/82 (18.3%) 14/27 (51.8%)
Unfavorable histology 29/80 (36.3%) 24/26 (92.3%)
Elevated baseline urine catecholamines 20/31 (64.5%)a 16/27 (59.3%)
MIBG avid tumor at diagnosis 53/82 (64.6%)b 19/27 (70.3%)
a
Available only in patients with high-risk disease.
bInstitutional report.
P= 0.31





















Figure 1: Box plot of tumor NET mRNA expression according
to tumor avidity for MIBG at initial diagnosis in 27 patients with
neuroblastoma (n = 19 with MIBG avid tumors and n = 8
with MIBG nonavid tumors). End of whiskers represent 5th and
95th percentiles. Transporter expression is expressed as a percent of
PGK1 expression.
correlated with MIBG avidity, we next evaluated whether
NET protein expression correlated with clinical MIBG
avidity. Of the 82 patients in our overall cohort, adequate
archival tumor material was available in 61 cases. Of these 61
patients, 23 had centrally reviewed MIBG scans (15 MIBG
avid and 8 MIBG nonavid). The percent of tumor cells
with NET protein expression correlated with MIBG avidity.
Specifically, the median percent expression was 50% (range
0–100%) in MIBG avid patients compared to 10% (range 0–
80%) inMIBG nonavid patients (P = 0.027). However, these
two groups showed extensive overlap in the distribution of
the percent of tumor cells expressing NET, including one
MIBG-avid patient with 0% NET expression (Figure 2(a)).
We next evaluated whether intensity of NET protein
expression correlates with MIBG avidity. Table 2 shows
the distribution of NET immunohistochemistry staining
intensity according to MIBG avidity. Patients with MIBG
avid tumors had a trend towards higher NET intensity scores
compared to patients with MIBG nonavid tumors (P =
0.06). Only 1 of 8 patients with centrally reviewed MIBG
nonavid tumors had a NET protein intensity score ≥2.
Table 2: NET protein expression intensity score according toMIBG
avidity in 23 patients with neuroblastoma and centrally reviewed
MIBG scans.
NET protein intensity grading
0 1+ 2+ 3+
MIBG Nonavid 3 4 0 1
MIBG Avid 2 3 7 3
We also evaluated a composite score of percent of tumor
cells with NET protein expression and intensity score. This
composite score correlated with MIBG avidity. Specifically,
the median composite score was 100 (range 0–300) in
MIBG avid patients compared to 10 (range 0–240) in MIBG
nonavid patients (P = 0.023; Figure 2(b)).
3.5. NET mRNA Expression Does Not Correlate with NET
Protein Expression. We next evaluated whether NET mRNA
expression levels correlated with NET composite protein
expression score. A scatterplot revealed little correlation
between mRNA and protein expression in 61 patients with
both measurements (correlation coefficient = 0.22; P =
0.09; Supplemental Figure 2). We also categorized mRNA
expression as above and below the group median and
evaluated potential differences in NET composite protein
score. The median composite protein score for patients
with high NET mRNA expression was 130 (range 0–300)
compared to 90 (range 0–300) for patients with low NET
mRNA expression (P = 0.15).
3.6. NET Protein Expression Correlates with Clinical Features
in Neuroblastoma. We next evaluated whether NET protein
expression composite score correlates with patient clinical
characteristics (Table 3). One of the strongest findings was
that patients with MYCN nonamplified tumors showed
significantly higher NET protein expression compared to
patients with MYCN amplified tumors (P < 0.001). Patients
with intermediate-risk disease and localized tumors also had
significantly higher NET protein expression.
In order to evaluate the prognostic impact of NET
protein expression composite score, a Kaplan-Meier curve of
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Table 3: NET protein expression composite score (n = 61) according to baseline patient characteristics.
N Median NET protein expression composite score (range)
Age ≤ 18 months 32 95 (0–300)
Age > 18 months 29 140 (0–300)
Intermediate-risk group 34 160 (0–300)∗∗
High-risk group 27 60 (0–300)
Localized tumor 29 160 (0–300)∗∗
Metastatic tumor 32 55 (0–300)
Adrenal primary tumor 28 100 (0–300)
Nonadrenal primary tumor 33 100 (0–300)
MYCN nonamplified 48 160 (0–300)∗∗∗
MYCN amplified 13 10 (0–140)
Favorable histology 36 160 (0–300)
Unfavorable histology 24 70 (0–300)
Normal urine catecholaminesa 10 65 (0–240)
Elevated urine catecholamines 17 60 (0–300)
aAvailable only for patients with high-risk disease.
∗∗P < 0.05 for difference in expression between clinical groups.
∗∗∗P < 0.001 for difference in expression between clinical groups.
P = 0.027
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Figure 2: Box plots of percent of tumor cells positive for NET protein (a) and composite NET protein expression score (b) according to
tumor avidity for MIBG at initial diagnosis in 23 patients with neuroblastoma (n = 15 with MIBG avid tumors and n = 8 with MIBG
nonavid tumors). End of whiskers represent 5th and 95th percentiles.
estimated EFS was constructed based on transporter expres-
sion dichotomized around the group median. Outcomes did
not differ by log-rank test (P = 0.69; data not shown).
3.7. Evaluation of Other Membrane Transporters and MIBG
Avidity. While our results demonstrate differential NET
protein expression between patients with MIBG avid versus
nonavid tumors, we observed substantial overlap in the
extent of NET protein expression between these groups.
In order to evaluate if other cation transporters might
also be responsible for MIBG uptake, we compared mRNA
expression for the following transporters between patients
withMIBG avid and nonavid tumors:OCT1; OCT3; MATE1;
VMAT1; VMAT2. While the median VMAT1 and VMAT2
expression levels were higher in MIBG avid tumors, none of
these differences were statistically significant (P > 0.10 for all
comparisons; Table 4).
4. Discussion
We report for the first time a positive association between
clinical MIBG tumor avidity and NET protein expression
by neuroblastoma cells. This finding supports the critical
role of NET in mediating specific active uptake of MIBG
into neuroblastoma cells [3]. Our results are also consistent
with previous preclinical studies demonstrating a correlation
between NET protein levels and MIBG uptake into myocar-
dial cells [29].
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Table 4: mRNA expression for a panel of cation transporters according to tumor MIBG avidity in 27 patients with neuroblastoma and
centrally reviewed MIBG scans.a
MIBG Avid (n = 19) MIBG Nonavid (n = 8)
Median OCT1 mRNA 0.17% 0.11%
(range) (0.04–0.48%) (0.03–0.90%)
Median OCT3 mRNA 0.60% 1.3%
(range) (0.04–127%) (0–6.47%)
Median MATE1 mRNA 5.9% 8.2%
(range) (0.39–57%) (0.43–102%)
Median VMAT1 mRNA 89% 13%
(range) (0.68–348%) (0.43–1590%)
Median VMAT2 mRNA 175% 27%
(range) (2.7–2661%) (0.98–1253%)
a
Transporter expression is expressed as a percent of PGK1 expression. OCT2 mRNA expression was observed in only two tumors.
While we observed a significant association between
MIBG avidity and NET protein expression, we also noted
overlap in NET protein expression between patients with
MIBG avid and MIBG nonavid tumors. Specifically, our
cohort includes both patients with high NET protein expres-
sion and MIBG nonavid tumors as well as patients with low
NET protein expression and MIBG avid tumors. Given that
MIBG avidity was centrally assessed by independent review,
misclassification of MIBG avidity is unlikely to account for
these findings. Our genotyping results suggest that individual
variations in the structure of the SLC6A2 gene are also
unlikely to account for these results.
Instead, our findings raise the possibility that MIBG
uptake may be influenced by factors in addition to NET
protein. It is possible that tumors with low NET protein
expression may accumulate MIBG via other transporters.
Candidate transporters include OCTs and VMATs as these
transporters have been implicated in MIBG uptake in other
neuroendocrine tumors [18–20]. Our evaluation of OCT
and VMAT mRNA expression did not reveal any statistically
significant associations with MIBG avidity, including subset
analysis focusing only on patients with low NET protein
expression and MIBG avid tumors (data not shown). Given
the trend showing higher VMAT1 and VMAT2 mRNA
median levels in MIBG avid tumors, future studies will
focus on tumor VMAT protein levels. Likewise, it is possible
that tumors with high NET protein expression that fail to
accumulate MIBG may have increased expression of MIBG
efflux transporters that account for low net uptake of MIBG.
While MATE-1 mRNA expression did not correlate with
MIBG avidity, evaluation of protein levels of MATE-1 and
other efflux transporters may be informative. Alternatively,
other physiologic parameters, such as tumor vascularity and
pH, may impede distribution of MIBG to the tumor cell
membrane. Our results do not address these alternative
possibilities and will require further study.
We were unable to replicate previous findings demon-
strating an association between NET mRNA expression and
clinical MIBG avidity [4]. Several explanations may account
for this discrepancy. First, our study relied on archived tumor
mRNA obtained within the context of cooperative group
trials. As such, degradation of mRNA may have resulted
in a false negative result, though our mRNA quality data
may argue against this point. Our findings suggest that
immunohistochemistry for NET protein may be a more
practical approach for evaluating NET expression in future
cooperative group studies and in clinical practice. Second, as
discussed above, it is possible that the association between
MIBG avidity and either NET protein or mRNA expression
is imperfect. We note that in previous studies of NET mRNA
levels as predictors of clinical MIBG uptake, cases of clinical
MIBG avidity in the setting of low NET mRNA expression
have been reported [4, 30]. In one previous study, 5 of 11
patients with negative PCR for NET mRNA nevertheless had
positive MIBG scans [4]. Third, it is possible that, as we
observed, NET mRNA expression does not correlate with
NET protein expression in human neuroblastoma tissue,
perhaps through posttranslational modification of NET
protein.
One of our secondary analyses yielded the previously
unreported association between MYCN amplification and
low NET protein expression. Other statistically significant
clinical correlations with lower NET protein expression
(patients with high-risk disease and patients with metastatic
disease) may be driven by this association with MYCN
amplification. As an exploratory secondary analysis unad-
justed for multiple statistical testing, it is also possible that
this association is a chance finding and therefore requires
replication by other groups.We note that one previous report
did not detect a difference in clinical MIBG avidity according
to tumorMYCN status [31]. In addition, response rates after
high-dose 131I-MIBG therapy do not appear to differ between
patients with MYCN amplified and MYCN nonamplified
tumors, though all patients were required to have MIBG avid
tumors to receive 131I-MIBG therapy [32]. The association
between MYCN status and clinical MIBG avidity will be
investigated further in a future analysis by our group.
5. Conclusions
We have demonstrated that neuroblastoma tumor cell NET
protein expression correlates with clinical MIBG avidity and
International Journal of Molecular Imaging 7
also with tumor MYCN status. Additional work, including
gene and protein expression profiling efforts, will need to
investigate other mechanisms of MIBG uptake in cases with
low NET protein expression. Future studies may also focus
on the correlation between tumor NET protein expression
and response to targeted radiotherapy with high-dose 131I-
MIBG.
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